Manuel Alonso-Perez

Av. Dr. Moliner 50
Valencia, VC 46100, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1.

Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1.

Journal: American journal of human genetics

Published: July 04, 2025

Playing catching up: Proceedings of the 1st Spanish conference on genomic medicine.

Playing catching up: Proceedings of the 1st Spanish conference on genomic medicine.

Journal: AIDS reviews

Published: September 26, 2024

miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis in myotonic dystrophy.

miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis in myotonic dystrophy.

Journal: Molecular therapy. Nucleic acids

Published: May 20, 2024

Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice.

Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice.

Journal: International journal of molecular sciences

Published: April 28, 2023

Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model.

Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model.

Journal: Biomedical journal

Published: March 23, 2023

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice.

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice.

Journal: Pharmaceutics

Published: December 21, 2022

Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice.

Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice.

Journal: Scientific reports

Published: June 07, 2022

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model.

Journal: Molecular therapy. Nucleic acids

Published: September 15, 2021

Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease.

Defined D-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease.

Journal: Scientific reports

Published: December 09, 2020

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.

Journal: Molecular therapy. Nucleic acids

Published: October 18, 2020

Design of novel small molecule base-pair recognizers of toxic CUG RNA transcripts characteristics of DM1.

Design of novel small molecule base-pair recognizers of toxic CUG RNA transcripts characteristics of DM1.

Journal: Computational and structural biotechnology journal

Published: September 20, 2020

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.

Journal: Molecular therapy. Nucleic acids

Published: April 16, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026